Kyverna Therapeutics (KYTX) awards CCO 300,000 stock options

Rhea-AI Filing Summary

Kyverna Therapeutics granted Chief Commercial Officer Nadia Dac a stock option to acquire 300,000 shares of common stock at an exercise price of $9.00 per share, expiring on May 4, 2036. This is a compensation award, not an open-market share purchase.

One quarter of the option vests on May 4, 2027, with the remaining shares vesting in equal monthly installments over the following 36 months, contingent on her continuous service with the company.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Dac Nadia

Role Chief Commercial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	300,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 300,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 300,000 shares Exercise price: $9.00 per share Expiration date: May 4, 2036 +2 more

5 metrics

Option grant size 300,000 shares Stock option to buy common stock granted to CCO

Exercise price $9.00 per share Exercise price of granted stock options

Expiration date May 4, 2036 Option term end date

Post-grant option holdings 300,000 options Total derivative securities following this transaction

Initial vesting date May 4, 2027 Date when 1/4 of the option vests

Key Terms

Stock Option (right to buy), exercise price, expiration date, vesting

4 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

exercise price financial

"conversion_or_exercise_price: 9.0000"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-05-04T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vesting financial

"1/4th of the shares subject to the option shall vest on May 4, 2027"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dac Nadia

(Last) (First) (Middle)

C/O KYVERNA THERAPEUTICS, INC.

5980 HORTON STREET, SUITE 550

(Street)

EMERYVILLE CALIFORNIA 94608

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kyverna Therapeutics, Inc. [ KYTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$9	05/04/2026		A		300,000		(1)	05/04/2036	Common Stock	300,000	$0	300,000	D

Explanation of Responses:

1. 1/4th of the shares subject to the option shall vest on May 4, 2027, and 1/48th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive

	By: /s/ Marc Grasso, as Attorney-in-Fact	05/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Kyverna Therapeutics (KYTX) report for Nadia Dac?

Kyverna Therapeutics reported that Chief Commercial Officer Nadia Dac received a grant of stock options for 300,000 shares. These options give her the right to buy Kyverna common stock at a fixed $9.00 exercise price as part of her compensation.

What is the exercise price and term of the new Kyverna (KYTX) stock options?

The granted stock options have a $9.00 per share exercise price and expire on May 4, 2036. This long term gives the executive a multi-year window to decide whether to exercise, depending on her employment status and Kyverna’s share performance.

How do the Kyverna (KYTX) options granted to Nadia Dac vest over time?

One quarter of the 300,000-share option vests on May 4, 2027. The remaining three quarters vest in equal monthly installments over the next 36 months, so full vesting occurs over four years, assuming continuous service with Kyverna Therapeutics.

Is the Kyverna (KYTX) Form 4 a stock purchase by the executive?

No, the Form 4 reports a compensatory stock option grant, not an open-market share purchase. Nadia Dac received the right to buy 300,000 shares at $9.00 but does not own the underlying shares unless and until she exercises vested options.

What role does Nadia Dac hold at Kyverna Therapeutics (KYTX) in this Form 4?

In this Form 4, Nadia Dac is identified as Kyverna Therapeutics’ Chief Commercial Officer. The reported transaction reflects an equity compensation award tied to her executive role, aligning part of her potential future pay with Kyverna’s stock performance.